US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
‘The Blue Angels,’ filmed for IMAX, puts viewers in the ‘box’ with the elite flying squad
If you’re looking for a little bit of that “ Top Gun: Maverick ” spectacle and thrill at the movie t2024-05-22Woman charged over Auckland hit
Jason Collins was found dead on 7 December, 2023. Photo: Supplied / Police2024-05-22- The latest false conspiracy involves claims of a body double in the footage published by the Sun new2024-05-22
Alarm over 'strange' illness that has killed four and sickened dozens more in Nigeria
Four people have been killed and dozens sickened by a 'strange' illness in Nigeria.All of the cases2024-05-22Election 2024: Biden and Trump bypassed the Commission on Presidential Debates
PHOENIX (AP) — The nonpartisan Commission on Presidential Debates, which has planned presidential fa2024-05-22VOX POPULI: Our anger must never cool over ‘vital’ political fund
What aspects of everyday life are deemed to be essential in Japan? And, what, exactly, are “fuyo-fuk2024-05-22
atest comment